### 2.2.1	In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of dapagliflozin. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit**    | **Value** | Source                                 | **Description**                                 |
| :-------------- | ----------- | --------- | -------------------------------------- | ----------------------------------------------- |
| MW              | g/mol       | 293.37    | Drugbank [DB00904]                     | Molecular weight                                |
| pK<sub>a</sub>  |             | 7.34      | Drugbank [DB00904]                     | Acid dissociation constant                      |
| Solubility (pH) | mg/L (pH 7) | 0.3551    | Drugbank [DB00904]                     | Aqueous Solubility, FaSSIF, ...                 |
| logP            |             | 1.59      | Optimized                              | Partition coefficient between octanol and water |
| fu              | %           | 27        | Elkomy et al. 2015                     | Fraction unbound in plasma                      |
| B/P ratio       |             | 0.83      | [Simpson & Hicks, 1996](#5 References) | Blood to plasma ratio                           |
| ...             |             |           |                                        | ....                                            |

### 2.2.2	Clinical Data

A literature search was performed to collect available clinical data on dapagliflozin in healthy adults.

#### 2.2.2.1	Model Building

The following studies were used for model building (training data):

| Publication                 | Arm / Treatment / Information used for model building        |
| :-------------------------- | :----------------------------------------------------------- |
| Colthup 1991                | Healthy Subjects with a single intravenous dose of 8 mg infused for 15 minutes |
| [Blake 1993](#7 References) | Healthy Subjects with a single intravenous dose of 8 mg infused for 5 minutes |
| VanDenBerg 2000             | Healthy Subjects with a single intravenous dose of 24 mg infused for 20 minutes |

#### 2.2.2.2	Model Verification

The following studies were used for model verification:

| Publication | Arm / Treatment / Information used for model building |
| :---------- | :---------------------------------------------------- |
| ...         | ...                                                   |
| ...         | ...                                                   |

